Table 1

Clinical and immunological data for each participant

VMM	Age at enrollment	Sex	ECOG PS	Primary melanoma site	Stage at enrollment	LDH level at enrollment (U/L)*	Biopsiable tumor†	PD-1 Ab naïve	PD-L1 status‡	BRAF V600E/K mutation status	High durable T cell response	Durable T cell Rsp	T cell Rsp	On treatment month	Best RECIST response	Survival status	Survival duration (months)§
1014	72	M	1	Skin, acral	IV	202	Yes	No	N/A	WT	No	No	Yes¶	May 2018	PD	Deceased	31.51
1088	63	F	0	Skin, non-acral	IV	146	Yes	No	20%	WT	No	No	No	February 2018	PD	Alive	45.77
1265	72	M	0	Skin, non-acral	IV	231	Yes	No	N/A	WT	No	No	No	October 2016	PD	Deceased	10.45
1274	36	F	0	Skin, non-acral	IV	177	No	No	N/A	V600E	No	No	No	March 2017	SD	Deceased	47.38
1275	62	F	1	Skin, non-acral	IV	515	No	No	N/A	V600E	No	No	No	March 2017	PD	Deceased	4.34
1284	48	F	1	Anal, mucosal	IV	334	No	No	N/A	WT	No	No	No	November 2017	PD	Deceased	10.22
1287	75	F	0	Skin, acral	IV	221	No	No	N/A	V600E	No	No	No	November 2017	SD	Deceased	20.86
1290	54	F	0	Skin, non-acral	IV	156	No	No	0%	V600E	No	No	Yes^e,f	March 2018	PR	Alive	45.01
1291	48	M	1	Skin, non-acral	IV	3177	Yes	No	<1%	V600E	No	No	No	April 2018	PD	Deceased	2.50
1293	57	M	0	Uveal	IV	400	No	No	0%	WT	No	No	No	May 2018	PD	Deceased	6.77
1296	64	M	0	Anal, mucosal	IV	198	No	No	50%–60%	WT	No	No	No	August 2018	PD	Deceased	10.55
1297	50	F	1	Skin, acral	IV	404	Yes	No	N/A	WT	No	No	No	August 2018	PD	Deceased	3.48
1301	56	M	0	Skin, acral	IV	280	Yes	No	>95%	WT	No	No	No	January 2019	SD	Deceased	26.38
1302	70	M	1	Skin, non-acral	IV	195	Yes	No	75%	WT	No	No	No	March 2019	PD	Deceased	3.61
1305	67	F	1	Skin, acral	IV	274	Yes	No	2%–3%	WT	No	No	No	Jun 2019	PD	Deceased	24.41
1306	63	M	0	Uveal	IV	186	Yes	No	5%	WT	No	Yes	Yes¶	Jun 2019	SD	Deceased	19.48
1272	74	F	0	Skin, non-acral	IV	155	Yes	Yes	<1%	V600E	No	No	No	December 2016	PD	Deceased	43.33
1276	81	M	0	Skin, non-acral	IV	250	Yes	Yes	N/A	N/A	No	No	Yes	April 2017	CR	Alive	54.44
1278	44	M	0	Skin, non-acral	IIIC	184	No	Yes	20%–25%	V600E	Yes	Yes	Yes¶	June 2017	PR	Alive	52.70
1285	69	M	0	Skin, non-acral	IV	177	No	Yes	5%–10%	WT	No	No	Yes¶	November 2017	PR	Alive	47.54
1295	79	M	1	Skin, non-acral	IV	223	No	Yes	10%	WT	No	No	No	July 2018	PR	Deceased	37.49
1299	60	M	1	Uveal	IV	992	Yes	Yes	<1%	WT	No	No	Yes¶	October 2018	PD	Alive	37.32

Bolded text highlights participants who were PD-1 Ab naïve, had a T cell Rsp, or had a PR or CR.
*The normal range for blood LDH level is between 125 and 250 U/L.
†Participants who had one or more additional sites of metastasis available for biopsy pretreatment and on day 22.
‡Per cent of tumor cells expressing PD-L1.
§Survival duration was calculated from the start of study treatment through the date of last follow-up or date of death.
¶Participants who had a fivefold T cell Rsp (hRsp).
**VMM 1290 had no T cell Rsp in peripheral blood mononuclear cells, but did have a T cell Rsp (Rsp and hRsp) in the sentinel immunized node.
Ab, antibody; CR, complete response; ECOG, Eastern Cooperative Oncology Group; F, female; hRsp, high T cell response; LDH, lactic acid dehydrogenase; M, male; N/A, not applicable or unknown; PD-1, programmed cell death protein 1; PD, progressive disease; PD-L1, programmed death-ligand 1; PR, partial response; PS, performance status; RECIST, Response Evaluation Criteria in Solid Tumors; response, Rsp; SD, stable disease; VMM, Virginia Malignant Melanoma; WT, wild type.